Genprex, Inc./$GNPX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Genprex, Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
- Ticker
- $GNPX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 13
- Headquarters
- Austin, United States
- Website
- www.genprex.com
Genprex, Inc. Metrics
BasicAdvanced
$1.9M
-
-$71.69
-0.89
-
Price and volume
Market cap
$1.9M
Beta
-0.89
52-week high
$9.99
52-week low
$1.71
Average daily volume
181K
Financial strength
Current ratio
6.765
Quick ratio
6.471
Interest coverage (TTM)
-21.41%
Profitability
Management effectiveness
Return on assets (TTM)
-94.46%
Return on equity (TTM)
-203.86%
Valuation
Price to book
0.08
Price to tangible book (TTM)
0.08
Price to free cash flow (TTM)
-0.034
Free cash flow yield (TTM)
-2,953.34%
Free cash flow per share (TTM)
-67.624
Growth
Earnings per share change (TTM)
-94.85%
Genprex, Inc. Financial Performance
Revenues and expenses
Genprex, Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.